Max Rauner, Science editor at ZEIT Wissen, the popular science magazine of Germany’s largest weekly newspaper Die ZEIT, won the Cancer World Journalism Award for best article on research, with this piece on the use [more]
If mind-boggling complexity is the barrier to developing personalised cancer care strategies, could mathematical modelling – long used by economists, meteorologists and others – be the answer? Marc Beishon talks to leading figures who are [more]
For a disease that has led the field of molecular biology, it is surprising perhaps that so few biomarkers have been identified that can predict a person’s risk of developing cancer. Researchers are now looking [more]
The risk of developing breast cancer varies widely from woman to woman in ways we are increasingly able to define. Marc Beishon asks: Is it time to move to population screening for risk, and tailor mammography schedules – [more]
Molecular imaging specialists are ready to break out of their research huddles and take their place at the heart of clinical decision making. But can they convince clinicians to welcome them in? Anna Wagstaff investigates. [more]
Nobel laureate Jim Watson is calling on the cancer community to take a long hard look at what has been achieved by blocking the molecular signals that drive individual cancers Sixty years after Jim Watson [more]
France’s relatively low profile on the European cancer stage belies a creative and innovative approach to research and care that other countries could learn from. Agnès Buzyn lifts the lid on how French cancer services [more]
Treating the right patient with the right therapy at the right time depends on having the right picture of every patient’s key biological markers. A number of initiatives are now springing up across Europe to [more]
Tailoring a patient’s treatment to the particular biology of their cancer holds out the enticing prospect of avoiding over-treatment and reducing unnecessary toxicity. But delivering the right option for the right patient at the right [more]
Angelo Di Leo cut his research teeth on the first studies that looked for biological markers that could predict which patients respond to what, and he’s never looked back. Download full article
The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal. Download full article
Recent years have seen a scramble to identify the genetic variance that predisposes or protects against certain cancers and the tumour gene signatures that could indicate which therapies will work and which won’t. A picture [more]
New technologies offer wonderful possibilities for cancer patients. But the development of personalised therapies is being squeezed between the priorities of industry and a regulatory system that offers poor value for money. Is there a [more]